Nishioka S, Sofue T, Inui M, Nishijima Y, Moriwaki K, Hara T, Mashiba T, Kakehi Y, Kohno M
Department of Cardiorenal and Cerebrovascular Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Department of Cardiorenal and Cerebrovascular Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Transplant Proc. 2014;46(2):514-20. doi: 10.1016/j.transproceed.2013.11.153.
Mineral and bone disorder (MBD) is a major complication of chronic kidney disease and remains a major problem even after kidney transplantation. Although early steroid withdrawal protocols have beneficial effects on mineral and bone metabolism, they are also associated with significantly increased rates of acute allograft rejection (AR). Recently, patients have been treated with early rapid corticosteroid reduction protocols, but it is still unclear whether these protocols reduce the rate of MBD. The aim of this study was to evaluate the effects of early rapid corticosteroid reduction on MBD after kidney transplantation.
We retrospectively evaluated 34 adult kidney transplant recipients who were treated with an early rapid corticosteroid reduction protocol. Glucocorticoid treatment was reduced to methylprednisolone 4 mg/d at 1 month after transplantation.
The AR rate at 3 years after transplantation was 15%. Bone mineral density was slightly decreased in the femur at 4 months after transplantation but returned to the preoperative level by 24 months after transplantation. There was no significant decrease in the bone mineral density of the lumbar spine during the first year after transplantation. Urinary deoxypyridinoline levels and plasma osteocalcin levels returned to the normal range during the follow-up period. Bone mineral density tended to be lower in female patients than male patients and in patients who underwent long-term pretransplant dialysis than those who did not undergo long-term pretransplant dialysis.
The present study found that MBD was temporary in kidney transplant recipients who were treated with an early rapid corticosteroid reduction protocol and that these patients did not have an increased AR rate.
矿物质和骨代谢紊乱(MBD)是慢性肾脏病的主要并发症,即使在肾移植后仍是一个主要问题。尽管早期停用类固醇方案对矿物质和骨代谢有有益影响,但它们也与急性移植肾排斥反应(AR)发生率显著增加有关。最近,患者接受了早期快速减少皮质类固醇方案的治疗,但这些方案是否能降低MBD的发生率仍不清楚。本研究的目的是评估早期快速减少皮质类固醇对肾移植后MBD的影响。
我们回顾性评估了34例接受早期快速减少皮质类固醇方案治疗的成年肾移植受者。移植后1个月时,糖皮质激素治疗减至甲泼尼龙4mg/d。
移植后3年的AR发生率为15%。移植后4个月时股骨骨密度略有下降,但移植后24个月时恢复到术前水平。移植后第一年腰椎骨密度无显著下降。随访期间尿脱氧吡啶啉水平和血浆骨钙素水平恢复到正常范围。女性患者的骨密度往往低于男性患者,长期移植前透析患者的骨密度低于未进行长期移植前透析的患者。
本研究发现,接受早期快速减少皮质类固醇方案治疗的肾移植受者的MBD是暂时的,且这些患者的AR发生率没有增加。